New Dual-Gas Eye Drops Show Promise for Glaucoma Treatment
- Authors
- Jiamin Liu, Yuan Liang, Yi Tian, Xinghuai Sun, Yuan Lei, Pengpeng Lei, Hongjie Zhang
- Journal
- Advanced Healthcare Materials
- Year
- 2025
- DOI
- 10.1002/adhm.202404245
- Study Type
- Cell Culture
- Outcome
- Positive
- Peer Reviewed
- Yes
- Country
- China
- Health Condition
- Glaucoma
- Body System
- Visual System
TL;DR
Scientists have created a new type of eye treatment that uses light to trigger the release of two gases, which together help lower the pressure inside the eye, offering a potential new way to treat glaucoma.
Key Finding
A light-activated nanoparticle that releases both hydrogen and nitric oxide showed promise in cell studies for lowering intraocular pressure by improving fluid drainage from the eye through synergistic activation of cellular signaling pathways.
Summary
Researchers developed a new nanoparticle treatment for glaucoma (a disease that damages the optic nerve and causes blindness) that releases two gases—hydrogen and nitric oxide—when activated by laser light. In cell culture experiments, this dual-gas system worked by relaxing eye tissue cells and improving fluid drainage from the eye, which could lower the dangerous pressure buildup inside the eye that characterizes glaucoma.
Practical Takeaway
This is early-stage research conducted only in cell cultures, not in animals or humans, so it cannot yet predict real-world effectiveness or safety in people. While the dual-gas approach is scientifically interesting, many years of additional testing would be needed before this technology could potentially become a glaucoma treatment.
Abstract
Glaucoma, a leading cause of irreversible blindness worldwide, is characterized by optic nerve damage often associated with elevated intraocular pressure (IOP). Although gas therapies hold promise for glaucoma treatment, the limitations of single-gas strategies constrain their therapeutic efficacy. Here, a photoresponsive dual-gas nanomedicine is developed for targeted glaucoma therapy. The nanomedicine, PdH-D-S, is engineered by synthesizing mesoporous palladium hydride (meso-PdH) with efficient hydrogen (H₂) storage capacity and abundant pore channels, followed by surface modification with DSPE-mPEG and loading sodium nitroprusside (SNP) as a nitric oxide (NO) donor. PdH-D-S penetrates the cornea to reach IOP-regulating tissues, including the trabecular meshwork and Schlemm's canal. Upon 808 nm laser excitation, PdH-D-S releases H₂ and NO in a controlled manner. H₂ activates the AKT/p-AKT/eNOS/sGC signaling pathway, while NO binds to soluble guanylate cyclase (sGC), converting guanosine triphosphate (GTP) to cyclic guanosine monophosphate (cGMP), relaxing trabecular meshwork cells and enhancing aqueous humor outflow. This dual-gas system demonstrates high therapeutic efficacy in lowering IOP and offers a mechanistic advancement in glaucoma treatment through synergistic gas therapy.